Background: A combination of analgesic agents with different mechanisms can induce additive or synergistic analgesia. The N-type voltage-dependent calcium channel (N-VDCC) is a novel therapeutic target for pain control. In addition to providing effective pain relief when used alone, N-VDCC blockers produce synergistic analgesia when used in combination with opiates. However, the interaction between N-VDCC blockers and nonsteroidal anti-inflammatory drugs (NSAIDs) remains unclear. Methods: Using isobolographic analysis and composite additive curve analysis, the antinociceptive interaction between ZC88, a selective N-VDCC blocker and ibuprofen, a classical NSAID, was investigated in two mouse models of visceral and somatic inflammatory pain. Results: In the acetic acid writhing test, both ZC88 (10.5-42 mg/kg, intraperitoneally) and ibuprofen (50-200 mg/kg, orally) produced dosedependent antinociception, with ED 50 values of 27.2 and 100.5 mg/kg, respectively. ZC88 in combination with ibuprofen (ZC88 + ibuprofen) also induced significant antinociception, and isobolographic analysis revealed a synergistic interaction at 50% effect level. The experimental ED 50 (ED 50 mix ) of this combination (34.5 mg/kg) was significantly lower than the theoretical ED 50 (ED 50 add ; 63.8 mg/kg). Additionally, composite additive curve analysis displayed synergistic interaction at other effect levels. In the formalin test, ZC88 or ibuprofen alone significantly reduced late-phase rather than early-phase pain, with ED 50 values of 31.3 and 123.9 mg/kg, respectively. Similarly, both isobolographic analysis and composite additive curve analysis revealed synergistic antinociception of ZC88 + ibuprofen (40.6 mg/kg of ED 50 mix vs. 77.6 mg/kg of ED 50 add ). Conclusion: ZC88 in combination with ibuprofen produces synergistic antinociception in mouse models of somatic and visceral inflammatory pain. Significance: Because ZC88 + ibuprofen achieves the same antinociceptive effect at lower doses, the use of this combination could result in fewer dose-related untoward effects. The potentiation of ZC88 on ibuprofen-induced antinociception indicates that N-VDCC blocker has potential benefit to treat severe inflammatory pain. 
Introduction
Pain complaints are the most prevalent symptoms, which usually require analgesics for relief. Opiates and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for management of acute and chronic pain. However, prolonged use of opiates is limited by development of tolerance and dependence, and use of NSAIDs is often accompanied by gastrointestinal untoward effects. Therefore, new analgesics or analgesic combinations are required to relieve pain effectively with fewer untoward effects.
One promising target for the development of novel analgesics is the N-type voltage-dependent calcium channel (N-VDCC). N-VDCCs are almost exclusively expressed in neuronal tissue and localized primarily in presynaptic terminals to trigger neurotransmitter release (Westenbroek et al., 1992; Gohil et al., 1994; Wheeler et al., 1994) . The input of peripheral noxious stimuli activates the N-VDCCs in the nociceptive Ad and C nerve fibre terminals located in the superficial layers of the spinal cord dorsal horn, which is the primary centre for transduction and integration of pain signalling. Activation of these NVDCCs triggers the releases of glutamate, calcitonin gene-related peptide (CGRP) and substance P, ultimately inducing the sensation of pain (Bourinet et al., 2014; Zamponi et al., 2015) . Consequently, blocking N-VDCCs results in the reduction of painrelated neurotransmission, and thus produces analgesia (Atanassoff et al., 2000; Smith et al., 2002) . Furthermore, N-VDCC knockout mice exhibit reduced pain hypersensitivity in models of inflammatory and neuropathic pain (Hatakeyama et al., 2001; Kim et al., 2001; Saegusa et al., 2001 ). Therefore, N-VDCC is considered as a novel therapeutic target for pain control.
Ziconotide, a 25-amino acid peptide, is an N-VDCC blocker that has been approved for the treatment of refractory severe pain such as cancer pain and chronic neuropathic pain (Staats et al., 2004; Schmidtko et al., 2010; Pope and Deer, 2013) . However, intrathecal delivery and narrow therapeutic window limit clinical use of ziconotide. Several newly developed small molecule blockers of N-VDCCs have demonstrated antinociception in animal models (Yamamoto and Takahara, 2009; Lee, 2014) . In addition to providing pain relief when used alone, these N-VDCC blockers, including peptide neurotoxins and small-molecule compounds, produce synergistic antinociception when used in combination with morphine (Meng et al., 2008; Kolosov et al., 2011) . However, the interaction between N-VDCC blockers and NSAIDs, another class of first-line drugs for pain control, is not well characterized.
ZC88 (patent CN1884262B), a novel small-molecule N-VDCC blocker, was designed and synthesized by our group. Our previous study showed that ZC88 inhibited N-VDCC currents with an IC 50 of 0.45 lmol/L, whereas it failed to block L-, P/Q-and R-type calcium channels currents at concentrations of up to 100 lmol/L (Zhang et al., 2015) . ZC88 not only produced antinociceptive activity when given alone in thermal-stimulated acute pain, inflammatory pain and peripheral neuropathic pain in rodent models, but also potentiated morphine antinociception in thermal-stimulated acute pain in mice (Meng et al., 2008) . However, the interaction between N-VDCC blockers and NSAIDs has not been investigated. Therefore, in this study, the antinociceptive interaction between ZC88 and ibuprofen, a classical NSAID, was determined in mouse models of acute somatic and visceral inflammatory pain.
Materials and methods

Animals and drugs
Male Kunming (KM) mice, weighing 18-22 g, were purchased from SPF (Beijing) Laboratory Animal Technology Co., Ltd (Beijing, China). Animals were housed under a 12-h light/dark cycle (lights on at 7:00 a.m. and lights off at 7:00 p.m.) at 22 AE 1°C and 40-70% humidity, with food and water available ad libitum. All experiments were approved by the Animal Care and Use Committee of Beijing Institute of Pharmacology and Toxicology, China, and were carried out in compliance with the NIH Guide for the Care and Use of Laboratory Animals. All the studies were performed with double-blind designs.
ZC88 (synthesized by Beijing Institute of Pharmacology and Toxicology) and ibuprofen sodium salt (Sigma-Aldrich, USA) were dissolved in normal saline. ZC88 and ibuprofen were administered via intraperitoneal (ip) and oral (po) routes, respectively, at a volume of 10 mL/kg.
Acetic acid writhing test in mice
This test was performed according to a previously described protocol (Meng et al., 2008) , with some modifications. Mice were injected with 20 mL/kg of 0.6% acetic acid solution (ip). The number of writhing during a 30-min period was counted, starting 5 min after the acetic acid injection. Antinociceptive activity was expressed as a percentage of the maximum possible effect (MPE%): MPE% = 100 À (number of writhing for each mouse/average number of writhing in the control group) 9 100. ED 50 values were calculated from the lg dose-response curve by performing linear regression analysis.
In the test group, ZC88 (10.5-42 mg/kg, ip) or ibuprofen (50-200 mg/kg, po) was administered 20-30 min or 50-60 min before the acetic acid injection, respectively; the mice in each control group received normal saline (10 mL/kg, ip or po). To determine the interaction between ZC88 and ibuprofen, we administered different doses of ZC88 + ibuprofen combined at a fixed-ratio of 1:1 (1/16, 1/8, 1/4, 1/2 and 3/4 of each ED 50 dose). Ibuprofen (po) was administered 30 min prior to ZC88 (ip) administration, and acetic acid was administered 20-30 min after ZC88 administration.
Formalin test in mice
Before beginning of the test, each mouse was acclimated to the testing chamber for about 30 min individually. Using a microsyringe, each mouse received 10 lL of a 5% formalin solution in normal saline into the plantar surface of the right hindpaw (Saddi and Abbott, 2000) . Immediately after the formalin injection, the mice were returned to the testing chamber and pain behaviours were observed for 50 min. The duration of spontaneous licking or flinching of the injected hindpaw was recorded during the early phase I (0-5 min) and the later phase II (10-50 min). The percentage of antinociception in either phase I or phase II was calculated as follows: Antinociception% = 100 À (duration of hindpaw licking or flinching for each mouse/average time of hindpaw licking or flinching in the control group) 9 100. The ED 50 value was calculated as mentioned above. In addition, formalin-induced paw oedema was measured, which was calculated as follows: paw oedema (mm) = injected-paw thickness 1 h after formalin injection À injected-paw thickness before formalin injection (Shajib et al., 2008) . Drugs were administrated as described in the acetic acid writhing test, except for ZC88 given alone at dosages from 15 to 42 mg/kg.
Analysis of the interaction between ZC88 and ibuprofen
Using the method described by Tallarida (2000) , we performed isobolographic analysis to characterize the interaction between ZC88 and ibuprofen in both the acetic acid writhing test and the formalin test.
Briefly, the experimental ED 50 for the combination of both drugs (ED 50 mix ) as well as the ED 50 values for ZC88 and ibuprofen alone were calculated from their lg dose-response curves using linear regression, respective, and then, the parallelism of the regression lines for ZC88 and ibuprofen alone was tested using t-test. A theoretical ED 50 (ED 50 add ) was calculated on the basis of the real ED 50 values for each drug under the assumption that only additive interaction occurs between the two drugs. The variance of ED 50 add (V(ED 50 add )) was calculated as follows:
Ibu ), with f = 0.5. The significance of difference between ED 50 mix and ED 50 add was analysed using ttest. If the ED 50 mix was significantly less than the ED 50 add , it was interpreted as a synergistic interaction between these two drugs. If no significant difference was found between the ED 50 mix and ED 50 add , it was interpreted as an additive interaction. An interaction index (c) was calculated using the following formula: c = a/ED 50 ZC88 + b/ED 50 Ibu (Tallarida, 2002) , in which a and b represent the respective doses of ZC88 and ibuprofen in the ED 50 mix . If c = 1, the interaction was considered additive, and if c < 1, the interaction was considered synergistic.
Furthermore, to determine the interaction at other effect levels, we used the composite additive curve analysis (Tallarida, 2000) , a more precise analysis method. In brief, a composite additive regression line was constructed by the additive set of points translated from the drug alone treatment. And the significant difference between the composite additive line and the experimental combination line was determined by F-distribution test.
Rotarod test in mice
The rotarod test was used to evaluate the effect of the drugs on motor coordination or sedation (Stepanovic-Petrovic et al., 2008) . One day before the test, animals were trained on the rotarod at a constant speed of 15 rpm three trials with 3 min/trial. Only those mice that could stay on the rod for 180 s on two consecutive trials were used in the following test. On the testing day, the latency to fall was recorded every 30 min after drug administration, with 180 s as the cut-off latency. In single-drug groups, mice were administered ZC88 (30 and 42 mg/kg, ip) or ibuprofen (100, 140 and 200 mg/kg, po) and tested at 30, 60 and 90 min or 60, 90 and 120 min after drug administration, respectively. In the ZC88 + ibuprofen combination groups (20.4 + 75.7 and 23.25 + 93 mg/kg), ibuprofen (po) was administered 30 prior to ZC88 (ip) administration. The latency to fall was recorded for each mouse 30, 60 and 90 min after ZC88 administration.
Statistical analysis
The data are expressed as mean AE standard error of the mean (SEM) or as ED 50 values with 95% confidence intervals (CI). The data from the antinociceptive activity and rotarod tests were analysed using one-way ANOVA followed by Bonferroni's test and two-way ANOVA with repeated measurements followed by Bonferroni's test, respectively. The ED 50 values (except for ED 50 add ) were calculated from lg dose-response curves by linear regression analysis. The parallelism of the lg dose-response curves for ZC88 and ibuprofen administered alone and the difference between ED 50 mix and ED 50 add were analysed by t-test, as described by Tallarida. Statistical significance was defined as p < 0.05.
Results
Synergistic antinociception between ZC88 and ibuprofen in the acetic acid writhing test in mice
Intraperitoneal injection of 0.6% acetic acid induced visceral inflammatory pain in mice, as indicated by the contraction of abdominal muscles accompanied by extension of the forelimbs and elongation of the body. Both ZC88 (10.5-42 mg/kg, ip) and ibuprofen (50-200 mg/kg, po) significantly reduced the number of writhing in a dose-dependent manner (ZC88: F (5,65) = 6.94, p < 0.001 by one-way ANOVA; ibuprofen: F (5,66) = 12.15, p < 0.001 by one-way ANOVA; Fig. 1A and B) . According to the corresponding lg dose-response curves ( Fig. 2A) , the ED 50 values of ZC88 and ibuprofen were 27.2 and 100.5 mg/kg, respectively (Table 1 ). In addition, the slopes of regression lines for ZC88 and ibuprofen administered alone were 95.1 AE 11.8 and 108.8 AE 12.4, respectively, and statistical analysis revealed the parallelism of their lg dose-response curves (p > 0.05 by t-test). Therefore, normal type I isobolographic analysis was performed in this experiment.
ZC88 + ibuprofen also induced dose-dependent antinociception in the acetic acid writhing test (F (5,64) = 7.58, p < 0.001 by one-way ANOVA; Fig. 1C ). Using the isobolographic analysis, the experimental ED 50 (ED 50 mix ) value calculated from the lg dose-response curve was 34.5 mg/kg, which was significantly lower than the theoretical ED 50 (ED 50 add ) value of 63.8 mg/kg (p < 0.05 by t-test; Fig. 2B and Table 1 ). In addition, the interaction Figure 1 ZC88, ibuprofen and ZC88 + ibuprofen produced antinociception in the acetic acid writhing test in mice. (A) ZC88 (intraperitoneal), (B) ibuprofen (oral), (C) ZC88 + ibuprofen (intraperitoneal and oral). n = 11-12, mean AE SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA followed by Bonferroni's test.
index of ZC88 + ibuprofen was 0.54 (Table 1) . These results suggested the synergistic interaction between ZC88 and ibuprofen at 50% effect level.
Since the lg dose-response curve of ZC88 + ibuprofen was significantly different from those of drug alone, the composite additive curve analysis was performed to further determine the interaction at other effect levels. Fig. 2C showed the experimental ZC88 + ibuprofen combination line and the calculated composite additive line. The F-distribution test showed the significant difference between the additive and the combination lines (F 2,11 = 39.36, which exceeded the tabular F value of 3.98 at 0.05 level), indicating the synergistic interaction between ZC88 and ibuprofen.
Synergistic antinociception between ZC88 and ibuprofen in the formalin test in mice
Intraplantar injection of 5% formalin solution induced a two-phase nociceptive response: the early phase (Phase I) was induced within the first 5 min and the late phase (Phase II) lasted from 10 to 50 min. In the early phase, neither ZC88 (15-42 mg/kg, ip) nor ibuprofen (50-200 mg/kg, po) significantly decreased the duration of hindpaw licking and flinching (ZC88: F (4,55) = 1.657, p > 0.05 by one-way ANOVA; ibuprofen: F (5,66) = 0.369, p > 0.05 by one-way ANOVA; Fig. 3A and B) . However, both ZC88 and ibuprofen dose dependently reduced the formalin-induced nociceptive response in the late phase (ZC88: F (4,55) = 2.98, p < 0.05; ibuprofen: F (5,66) = 3.89, p < 0.01 by one-way ANOVA; Fig. 3A and B), with ED 50 values of 31.3 and 123.9 mg/kg, respectively ( Fig. 4A ; Table 2 ). The slopes of the regression lines corresponding to the lg dose-response curves for ZC88 and ibuprofen administered alone were parallel (slope: 143.7 AE 12.1 vs. 93.5 AE 17.3 of ZC88 vs. ibuprofen; p > 0.05 by t-test). In the late phase of the formalin test, ZC88 + ibuprofen produced significant antinociception (F (5,66) = 7.14, p < 0.001 by one-way ANOVA; Fig. 3C ), and the two compounds showed a synergistic interaction at 50% effect level by the isobolographic analysis. The ED 50 mix value of the combination (32.8 mg/kg) was significantly lower than the ED 50 add value (73.3 mg/kg, p < 0.05 by ttest; Fig. 4B ; Table 2 ), and the interaction index (0.52) was less than 1 (Table 2) . Furthermore, the composite additive curve analysis showed the synergistic interaction at all effect levels ( Fig. 4C ; F 2,10 = 36.62, which exceeded the tabular F value of 4.10 at 0.05 level).
Additionally, ibuprofen (100, 140 and 200 mg/kg, po) and ZC88 + ibuprofen (23.25 + 93 mg/kg, ip + po) attenuated formalin-induced paw oedema, whereas ZC88 (15-42 mg/kg, ip) had no effect on the paw oedema (Fig. 3) , indicating that ZC88 neither attenuated formalin-induced local oedema and inflammatory nor enhanced ibuprofen's action on the local oedema and inflammatory.
Effects of ZC88 and ibuprofen in the rotarod test in mice
In the rotarod test, ZC88 (30 and 42 mg/kg), ibuprofen (100, 140, and 200 mg/kg), and ZC88 + ibuprofen (20.4 + 75.7 and 23.25 + 93 mg/kg) did not reduce the latency to fall (ZC88: 
Discussion
A combination of two or more drugs with multiple target mechanisms is commonly used to treat pain. In the present study, we showed for the first time that a combination of ZC88 and ibuprofen produced synergistic antinociception in two mouse models of acute visceral and somatic inflammatory pain: the acetic acid writhing test and the formalin test.
In inflammatory pain, tissue damage or inflammation activates the peripheral nociceptive afferents and the secondary sensory neurons in the dorsal horn of the spinal cord (Millan, 1999) . In the acetic acid writhing test, the inflammation and injury induced by acetic acid are associated not only with local release of inflammatory factor prostaglandins (PGs), particularly of the E series, resulting in the activation of visceral peripheral nociceptive afferents, but also with release of excitatory glutamate, principally in the spinal cord (Giamberardino, 1999) . Previous studies reported that N-VDCC activation triggered the release of nociceptive neurotransmitters and neurotransmodulators (e.g. glutamate, CGRP and substance P) in the dorsal horn of the spinal cord, and blocking N-VDCC resulted in the reduction of pain-related neurotransmission (Atanassoff et al., 2000; Smith et al., 2002; Bourinet et al., 2014; Zamponi et al., 2015) . Additionally, NSAIDs, such as ibuprofen, could inhibit peripheral cyclooxygenase 2 (COX-2) and reduce PGs synthesis to relieve inflammatory pain. Thus, ZC88 and ibuprofen reduced the acetic acid-induced pain response likely via central and peripheral mechanisms, respectively. In the formalin test, the two phases of the pain response are considered to be associated, at least partially, with distinct mechanisms (Hunskaar and Hole, 1987; Haley and Dickenson, 2016) . The early phase is due to direct stimulation of the nociceptors of peripheral C fibre nerve endings by formalin, resulting in the high intensity of C fibres firing. In contrast, the late phase is associated with formalin-induced release of peripheral mediators such as PGs and bradykinin, which causes the lower intensity of C fibre firing accompanied by facilitation of dorsal horn neuronal responses, reflecting the integration of peripheral and central (spinal/supraspinal) signalling. Therefore, by the blockade of PGs synthesis via inhibiting COX-2, NSAIDs (e.g. ibuprofen), could relieve late-phase rather than early-phase pain (Malmberg and Yaksh, 1995a; Tegeder et al., 2001) , which is consistent with the findings of the present study. As mentioned above, since N-VDCC activation triggers the release of nociceptive neurotransmitters and neurotransmodulators from the central terminals of primary afferent neurons (Bourinet et al., 2014; Zamponi et al., 2015) , N-VDCC blockers may suppress both early-and late-phase pain in the formalin test. In the present study, however, systemic administration of ZC88 significantly relieved formalin-induced late-phase pain, with no significant reduction of the nociceptive response in the early phase. Similarly, intrathecal administration of ziconotide, a selective N-VDCC peptide blocker, appeared to be more effective at suppressing the late phase rather than the early phase of the behavioural response to formalin (Malmberg and Yaksh, 1995b; Bowersox et al., 1996; Wang et al., 2000) . Additionally, similar to their weaker effects during the early phase of the formalin test, ziconotide and ZC88 were not very effective at increasing the pain threshold in the models of more intense acute pain, such as the hot plate and radiant heat tests in rats and mice (Malmberg and Yaksh, 1995b; Scott et al., 2002; Meng et al., 2008) . We presumed that the weaker effect of N-VDCC blockers on early-phase pain in the formalin test and thermal-stimulated acute pain might be due to the participation of other calcium channels subtypes in the intense stimuli-triggered presynaptic calcium influx Figure 3 ZC88, ibuprofen and ZC88 + ibuprofen produced antinociception in the formalin test in mice. (A) ZC88 (intraperitoneal), (B) ibuprofen (oral), (C) ZC88 + ibuprofen (intraperitoneal and oral). n = 11-12, mean AE SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA followed by Bonferroni's test.
and neurotransmitter release in the dorsal horn of the spinal cord. Indeed, both N-type and T-type calcium channels are expressed in cell bodies of dorsal root ganglion and afferent nerve terminals in the spinal cord dorsal horn and play an important role in pain signal processing, although N-type channels contribute in a more exclusive and greater degree (Choi et al., 2007; Zamponi et al., 2009 Zamponi et al., , 2015 Jacus et al., 2012; Garcia-Caballero et al., 2014) . When two compounds are administered at the same time, synergistic, additive or antagonistic interactions can occur. In preclinical studies, isobolographic analysis is considered the gold standard for the evaluation of the specific characteristics of interactions between two compounds at 50% effect level (Berenbaum, 1989) , and composite additive curve analysis is a more precise analysis at all effect levels (Tallarida, 2000) . Upon performing these analyses, the results revealed a synergistic interaction between ZC88 and ibuprofen in both the acetic acid writhing test and the formalin test. As mentioned above, ZC88 and ibuprofen produced antinociceptive activity via different complementary pathways at central and peripheral levels, respectively. Therefore, the synergistic interaction between ZC88 and ibuprofen could be explained by the involvement of different targets and sites (spinal N-VDCC vs. peripheral COX-2) in their antinociceptive effects against somatic and visceral inflammatory pain in mice.
In addition to the pharmacodynamic interaction, the pharmacokinetic interaction between two compounds may also contribute to synergistic action. To avoid the interference of gastrointestinal absorption of the tested compounds, we administered ibuprofen by the po route, and ZC88 by the ip route. However, it is not known whether a metabolic interaction exists between ZC88 and ibuprofen, or if ibuprofen affects ZC88 transporting into the central nervous system. Therefore, we could not rule out the contribution of a pharmacokinetic interaction between ZC88 and ibuprofen to their synergistic action. Notably, in the acetic acid and formalin tests, the slope of the dose-response curve of ZC88 + ibuprofen was lower than that of the individual compounds and the interaction tended to an additive property at higher effect level, indicating the existence of some mechanisms that affected the antinociceptive action at high dosages. The reason for these differences in slopes needs to be investigated in future studies.
For drugs that display synergistic interaction, lower doses of each drug can be used to achieve an equal or better pharmacological action with fewer untoward effects derived from individual compounds (Tallarida, 2001) . In particular, a combination of two analgesics with different mechanisms of action might be more beneficial because their individual untoward effects may be different. Ibuprofen caused gastrointestinal untoward effects because it nonselectively inhibited peripheral COX-1 activity (McGettigan and Henry, 2000) . In mice and rats, ZC88 produced central nervous system-related untoward effects (our unpublished data) at over antinociception doses, which were similar to those induced by ziconotide. Thus, we presumed that ZC88 in combination with ibuprofen at high doses may cause gastrointestinal and central nervous system-related untoward effects. Because of the synergistic antinociception, theoretically, the ZC88 and ibuprofen combination is less likely to cause untoward effects because the doses of the individual components are lower than that used for monotherapy. In addition, since ZC88 and ibuprofen have different untoward effects, using them in combination is unlikely to potentiate their individual side effects. In patients with rheumatic arthritis, increasing doses of ibuprofen lead to increased incidence of gastrointestinal untoward effects (McGettigan and Henry, 2000) ; therefore, the maximal tolerated ibuprofen dose is usually not enough to ameliorate the severe inflammatory pain sufficiently. The synergistic interaction between ZC88 and ibuprofen indicated that this combination may have potential benefit to treat severe inflammatory pain. In addition, we previously reported that ZC88 showed no abuse potential in mouse conditioned place preference model, and that, when used in combination with morphine, it could potentiate morphine-induced antinociception with decreasing morphine tolerance and dependence (Meng et al., 2008) . Indeed, leconotide, a peptide neurotoxin that blocking N-VDCC, also displayed the synergistic antinociception with morphine in a rat model of bone cancer pain (Kolosov et al., 2011) . In addition to the antinociceptive effect of ZC88 monotherapy on inflammatory and neuropathic pain in rodent models, the potentiations of ZC88 on antinociception produced by ibuprofen and morphine, two first-line analgesic agents commonly used in a clinical setting, support the utility of ZC88 as an effective analgesic candidate.
Since the acetic acid writhing test and the formalin test in mice belongs to acute inflammatory pain model, the present finding indicated that ZC88 in combination with ibuprofen produced synergistic interaction to acute inflammatory pain relief. Complete Freund's Adjuvant (CFA) is widely accepted to induce chronic inflammation pain in rodents, and we performed the CFA-induced chronic inflammatory pain model in KM mice. Unfortunately, the KM mice were too sensitive to CFA injection. Even 5-lL injection of 1 mg/mL CFA produced severe mechanical allodynia; and ZC88 (42 mg/kg, ip), ibuprofen (200 mg/kg, po) and ZC88 + ibuprofen (21 + 100 mg/kg, ip+po) only showed mild antinociceptive activity, when drugs either prophylactic or therapeutic administration ( Fig. S1 and Appendix S1). In fact, our unpublished data showed that ZC88 and ibuprofen significantly produced antinociceptive activity in CFA-induced chronic inflammatory pain in SD rats. Thus, we suppose that the mouse strain of KM mouse may be unsuitable to CFA-induced chronic inflammatory pain model. The antinociceptive interaction between ZC88 and ibuprofen to chronic inflammatory pain should be investigated in mice of other strains or rats model. This is the limitation of the present study.
In conclusion, we found that ZC88, a small-molecule selective N-VDCC blocker, in combination with ibuprofen, a classic NSAID, produced synergistic antinociception in two mouse models of acute somatic and visceral inflammatory pain. This finding may expand our understanding of the properties of N-VDCC blockers, which constitute a new class of promising analgesic candidates. Additionally, our findings suggest that N-VDCC blockers can be used in combination with NSAIDs for effective pain management with fewer untoward effects because lower dosages of the individual drugs are required to achieve the same analgesic effect.
